专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP1413316A1 Bifunctional conjugates or fusion proteins 审中-公开
标题翻译： Bifunktionelle Konjugate oder Fusionsproteine
公开(公告)号：EP1413316A1
公开(公告)日：2004-04-28
申请号：EP02405838.0
申请日：2002-09-27
申请人： Robert, Bruno , Donda, Alena , Cesson, Valérie , Mach, Jean-Pierre
发明人： Robert, Bruno , Donda, Alena , Cesson, Valérie , Mach, Jean-Pierre
IPC分类号： A61K47/48
CPC分类号： C07K16/32 , A61K47/6811 , A61K47/6849 , A61K47/6851 , A61K47/6853 , A61K2039/505 , C07K14/70539 , C07K16/28 , C07K16/3007 , C07K2317/54 , C07K2317/55 , C07K2319/00
摘要： The invention relates to the coupling or to the genetically fusing of two different proteins: one, which has the property of binding selectively to a target cell, such as an antibody or a ligand for a receptor overexpressed on target cells, and one consisting of a monomorphic MHC class I related protein, such as MIC-A or -B, or ULBP, or CD1d. This conjugate or fusion protein is designed to be localized in vivo on the surface of the target cells such as tumor cells or cells involved in neoangiogenesis. The high density of these monomorphic MHC class I related proteins will activate effector cells such as NK, NKT or other T cells with the objective to kill the targeted cells. The advantage of these MHC class I related molecules is that since they are monomorphic, the same conjugate or fusion protein can be used in every patient. Furthermore, the NK or NKT cells being involved in innate immunity , the reaction will be more rapid than that of acquired immunity and will involve a much higher population than antigen-specific MHC restricted T cells
摘要翻译：包含一种或多种CD1d复合物和抗体或其对细胞表面标志物特异性的片段的化合物是新的。 CD1d复合物包含CD1d和β2-微球蛋白分子，并与抗体或其片段连接。还包括以下独立权利要求：（1）在哺乳动物中诱导抗肿瘤反应的方法，包括向哺乳动物施用上述化合物; 和（2）哺乳动物中预防或治疗自身免疫/炎性或感染性疾病的方法，包括向哺乳动物施用上述化合物。活动：细胞抑制抗炎; 免疫抑制; 抗菌; 神经保护; 降血糖; 抗关节炎; 抗风湿; 眼科; 胃肠道根; Nephrotropic; 抗甲状腺; 拟甲状腺素; 肌肉根; 银屑病; 皮肤; 抗贫血; 嗜肝; 抗溃疡。没有给出生物数据。作用机制：抗体治疗。

2. 发明申请

WO2013005194A2 MULTISPECIFIC ANTIBODIES 审中-公开
标题翻译：多重抗体
公开(公告)号：WO2013005194A2
公开(公告)日：2013-01-10
申请号：PCT/IB2012/053482
申请日：2012-07-06
申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , KADOUCHE, Jean , MACH, Jean-Pierre , MICHIELIN, Olivier , ZOETE, Vincent , IWASZKIEWICZ, Justyna , CERUTTI, Martine , CHOBLET, Sylvie , GOLAY, Josée
发明人： KADOUCHE, Jean , MACH, Jean-Pierre , MICHIELIN, Olivier , ZOETE, Vincent , IWASZKIEWICZ, Justyna , CERUTTI, Martine , CHOBLET, Sylvie , GOLAY, Josée
IPC分类号： C07K16/46 , A61K39/395
CPC分类号： C07K16/468 , C07K16/2833 , C07K16/2896 , C07K2317/31 , C07K2317/522 , C07K2317/55 , C07K2317/732
摘要： The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CHI and CL domains, said mutations preventing heavy chain/light chain mispairing.
摘要翻译：本发明涉及包含在CHI和CL结构域的界面处具有突变的Fab片段的多特异性抗体构建体，所述突变防止重链/轻链失配。

3. 发明申请

WO2004087766A3 PEPTABODY FOR CANCER TREATMENT 审中-公开
标题翻译：癌症治疗用药
公开(公告)号：WO2004087766A3
公开(公告)日：2004-12-16
申请号：PCT/IB2004001049
申请日：2004-04-05
申请人： UNIV LAUSANNE , DEPERTHES DAVID , CLOUTIER SYLVAIN , MACH JEAN-PIERRE , HOLLER NILS , FATTAH OMAR
发明人： DEPERTHES DAVID , CLOUTIER SYLVAIN , MACH JEAN-PIERRE , HOLLER NILS , FATTAH OMAR
IPC分类号： C07K14/485 , C07K14/78 , C12N15/62 , C07K19/00
CPC分类号： C07K16/2863 , C07K14/485 , C07K14/78 , C07K2317/34 , C07K2317/73 , C07K2317/76 , C07K2319/21 , C07K2319/70 , C07K2319/73 , C12N15/62 , G01N33/57492
摘要： The present invention relates to an isolated and recombinant fusion peptabody, which binds to a member of the epidermal growth factor receptor useful in inhibiting the growth of certain tumor cells. Also disclosed are, nucleic acids encoding said isolated and recombinant fusion peptabody, kits and pharmaceutical compositions comprising said isolated and recombinant fusion peptabody as an active substance. Finally, a method for the manufacture of said isolated and recombinant fusion peptabody, and its use for the preparation of a medicament for the treatment or prevention of cancer are provided.
摘要翻译：本发明涉及分离和重组的融合肽抗生素，其结合用于抑制某些肿瘤细胞生长的表皮生长因子受体的成员。还公开了编码所述分离和重组融合肽抗体的核酸，试剂盒和药物组合物，其包含所述分离和重组融合肽抗体作为活性物质。最后，提供了用于制备所述分离和重组融合肽抗体的方法及其用于制备用于治疗或预防癌症的药物的用途。

4. 发明申请

WO1998018943A1 METHOD FOR THE OLIGOMERISATION OF PEPTIDES 审中-公开
标题翻译：用于低聚物的方法
公开(公告)号：WO1998018943A1
公开(公告)日：1998-05-07
申请号：PCT/EP1997005897
申请日：1997-10-24
申请人： NOVARTIS AG , UNIVERSITY OF LAUSANNE , SWISS INSTITUTE FOR ALLERGY AND ASTHMA RESEARCH , ISREC (INSTITUT SUISSE DE RECHERCHES EXPERIMENTALES SUR LE CANCER) , TERSKIKH, Alexey , CRAMERI, Reto , MACH, Jean-Pierre , LE DOUSSAL, Jean-Marc , KAJAVA, Andrey
发明人： NOVARTIS AG , UNIVERSITY OF LAUSANNE , SWISS INSTITUTE FOR ALLERGY AND ASTHMA RESEARCH , ISREC (INSTITUT SUISSE DE RECHERCHES EXPERIMENTALES SUR LE CANCER)
IPC分类号： C12N15/62
CPC分类号： C07K14/78 , C07K19/00 , C07K2319/00 , C07K2319/21 , C07K2319/73 , C12N15/62
摘要： The present invention concerns an oligomer comprising more than 2 units, wherein each unit comprises a peptidic domain capable of oligomerizing and a domain capable of binding to an acceptor (ligand), wherein the oligomerizing domain is not an antibody or a functional antibody fragment from the constant region. Also described is the use and synthesis of this oligomer.
摘要翻译：本发明涉及包含多于2个单元的寡聚体，其中每个单元包括能够低聚的肽结构域和能够结合受体（配体）的结构域，其中寡聚结构域不是来自抗体的功能性抗体片段恒定区。还描述了该低聚物的用途和合成。

5. 发明申请

WO1995017212A1 CONJUGATES CONSISTING OF PEPTIDIC T CELL ANTIGENS AND CELL BINDING PARTNERS AND THEIR USE FOR THERAPY 审中-公开
标题翻译：临床应用细胞因子抗原和细胞结合合作伙伴及其治疗用途
公开(公告)号：WO1995017212A1
公开(公告)日：1995-06-29
申请号：PCT/EP1994004280
申请日：1994-12-22
申请人： BOEHRINGER MANNHEIM GMBH , MACH, Jean-Pierre , HEALY, Frank , CORRADIN, Giampietro
发明人： BOEHRINGER MANNHEIM GMBH
IPC分类号： A61K47/48
CPC分类号： A61K47/6811
摘要： A conjugate comprising an essentially non-toxic peptide T cell antigen, which is capable of forming a complex with MHC class I or II molecules, and a binding partner for a surface receptor on mammalian target cells, whereby a) the binding partner has a high degree of selectivity for said target cells; by binding to substances which are expressed on the surface of said cells; b) the conjugate comprising the binding partner and the T cell antigen is internalized in said cells after binding of the binding partner to its surface receptor on said cells; c) the T cell antigen is processed from the conjugate and expressed on the cell surface in the form of a complex with MHC molecules, whereby said complex is recognized by the T cell receptor, thereby inducing cytotoxicity of T cells for the aforesaid target cells, is useful to induce specific cytotoxicity of T cells in the treatment of cancer autoimmune diseases, diabetes or allergic reactions.
摘要翻译：一种缀合物，其包含能够与MHC I类或II类分子形成复合物的基本上无毒的T细胞抗原，以及哺乳动物靶细胞上表面受体的结合配偶体，其中a）结合配偶体具有高的对所述靶细胞的选择性程度; 通过结合在所述细胞表面上表达的物质; b）在结合配偶体与所述细胞上的表面受体结合后，包含结合配偶体和T细胞抗原的缀合物在所述细胞内部被内化; c）从缀合物处理T细胞抗原，并以细胞表面形式与MHC分子形成复合体，由此所述复合物被T细胞受体识别，从而诱导T细胞对前述靶细胞的细胞毒性，可用于诱导T细胞特异性细胞毒性治疗癌症自身免疫疾病，糖尿病或过敏反应。

6. 发明申请

WO2008103392A3 MODULATION OF NKT CELL ACTIVITY WITH ANTIGEN-LOADED CDID MOLECULES 审中-公开
标题翻译： NKT细胞活性与抗原载体CDID分子的调节
公开(公告)号：WO2008103392A3
公开(公告)日：2008-12-04
申请号：PCT/US2008002256
申请日：2008-02-21
申请人： DONDA ALENA , MACH JEAN-PIERRE , STIRNEMANN KATHRIN , ZAUDERER MAURICE
发明人： DONDA ALENA , MACH JEAN-PIERRE , STIRNEMANN KATHRIN , ZAUDERER MAURICE
IPC分类号： A61K38/00 , A61K39/00 , A61K45/00 , C07K4/00 , C07K14/00
CPC分类号： A61K39/385 , A61K39/39 , A61K2039/55516 , A61K2039/55561 , A61K2039/55572 , A61K2039/55594 , A61K2039/6018 , C07K16/32 , C07K2319/00
摘要： The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CDId complexes, in particular non-specific soluble CDId complexes. Soluble CDId complexes comprise a soluble CDId polypeptide, a ß2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CDId antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD Id-restricted NKT cells, and in particular, allows for multiple administrations without causing CD Id-restricted NKT cell anergy.
摘要翻译：本发明涉及调节动物免疫应答的方法，其包括施用包含一种或多种可溶性CD1a络合物，特别是非特异性可溶性CD1a复合物的组合物。可溶性CD1d复合物包含与CD1d抗原结合槽结合的可溶性CD1d多肽，β2-微球蛋白多肽和神经酰胺样糖脂抗原，并且在某些实施方案中，是免疫原。本发明组合物的施用影响CD1d限制性NKT细胞的活性，特别是允许多次施用而不引起CD1受限制的NKT细胞无反应性。

7. 发明申请

WO2004029206A3 TARGETED CD1D MOLECULES 审中-公开
标题翻译：目标CD1D分子
公开(公告)号：WO2004029206A3
公开(公告)日：2004-10-07
申请号：PCT/US0330238
申请日：2003-09-26
申请人： VACCINEX INC , ZAUDERER MAURICE , ROBERT BRUNO , DONDA ALENA , CESSON VALERIE , MACH JEAN-PIERRE
发明人： ZAUDERER MAURICE , ROBERT BRUNO , DONDA ALENA , CESSON VALERIE , MACH JEAN-PIERRE
IPC分类号： A61K39/00 , A61K39/385 , A61K39/44 , C07K14/74 , C07K16/28 , C07K16/30
CPC分类号： C07K16/32 , A61K47/6811 , A61K47/6849 , A61K47/6851 , A61K47/6853 , A61K2039/505 , C07K14/70539 , C07K16/28 , C07K16/3007 , C07K2317/54 , C07K2317/55 , C07K2319/00
摘要： The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a ss2-microglobulin molecule, and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compounds, in particular anti-tumor and autoimmunity responses.
摘要翻译：本发明涉及包含一种或多种与特异于细胞表面标志物的抗体结合的CD1d复合物的化合物。 CD1d复合物包含CD1d，β2-微球蛋白分子，并且还可以包含与CD1d结合槽结合的抗原。本发明进一步涉及用CD1d抗体化合物抑制或刺激免疫应答的方法，特别是抗肿瘤和自身免疫应答。

8. 发明申请

WO2013005194A3 MULTISPECIFIC MUTATED ANTIBODY FAB FRAGMENTS 审中-公开
标题翻译：多重突变的抗体FAB片段
公开(公告)号：WO2013005194A3
公开(公告)日：2013-04-18
申请号：PCT/IB2012053482
申请日：2012-07-06
申请人： CENTRE NAT RECH SCIENT , KADOUCHE JEAN , MACH JEAN-PIERRE , MICHIELIN OLIVIER , ZOETE VINCENT , IWASZKIEWICZ JUSTYNA , CERUTTI MARTINE , CHOBLET SYLVIE , GOLAY JOSEE
发明人： KADOUCHE JEAN , MACH JEAN-PIERRE , MICHIELIN OLIVIER , ZOETE VINCENT , IWASZKIEWICZ JUSTYNA , CERUTTI MARTINE , CHOBLET SYLVIE , GOLAY JOSEE
IPC分类号： C07K16/46 , A61K39/395
CPC分类号： C07K16/468 , C07K16/2833 , C07K16/2896 , C07K2317/31 , C07K2317/522 , C07K2317/55 , C07K2317/732
摘要： The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CHI and CL domains, said mutations preventing heavy chain/light chain mispairing.
摘要翻译：本发明涉及包含在CHI和CL结构域的界面处具有突变的Fab片段的多特异性抗体构建体，所述突变防止重链/轻链失配。

9. 发明申请

WO2004087766A2 PEPTABODY FOR CANCER TREATMENT 审中-公开
标题翻译： PEPTABODY癌症治疗
公开(公告)号：WO2004087766A2
公开(公告)日：2004-10-14
申请号：PCT/IB2004/001049
申请日：2004-04-05
申请人： UNIVERSITE DE LAUSANNE , DEPERTHES, David , CLOUTIER, Sylvain , MACH, Jean-Pierre , HOLLER, Nils , FATTAH, Omar
发明人： DEPERTHES, David , CLOUTIER, Sylvain , MACH, Jean-Pierre , HOLLER, Nils , FATTAH, Omar
IPC分类号： C07K19/00
CPC分类号： C07K16/2863 , C07K14/485 , C07K14/78 , C07K2317/34 , C07K2317/73 , C07K2317/76 , C07K2319/21 , C07K2319/70 , C07K2319/73 , C12N15/62 , G01N33/57492
摘要： The present invention relates to an isolated and recombinant fusion peptabody, which binds to a member of the epidermal growth factor receptor useful in inhibiting the growth of certain tumor cells. Also disclosed are, nucleic acids encoding said isolated and recombinant fusion peptabody, kits and pharmaceutical compositions comprising said isolated and recombinant fusion peptabody as an active substance. Finally, a method for the manufacture of said isolated and recombinant fusion peptabody, and its use for the preparation of a medicament for the treatment or prevention of cancer are provided.
摘要翻译：本发明涉及一种分离的重组融合多聚肽体，其与可用于抑制某些肿瘤细胞生长的表皮生长因子受体成员结合。还公开了编码所述分离的和重组的融合多聚肽体的核酸，试剂盒和包含所述分离的和重组的融合多聚肽体作为活性物质的药物组合物。最后，提供了一种制备所述分离的重组融合多聚肽体的方法及其在制备用于治疗或预防癌症的药物中的用途。

10. 发明申请

WO2004073728A3 COMPOSITIONS COMPRISING FETAL HEMOGLOBIN AND BACTERIAL ENDOTOXIN AND OPTIONALLY ADDITIONAL FETAL LIVER COMPONENTS 审中-公开
标题翻译：包含天门冬氨酸和细菌内毒素和可选择性添加剂的组合物
公开(公告)号：WO2004073728A3
公开(公告)日：2004-10-07
申请号：PCT/EP2004001553
申请日：2004-02-18
申请人： CLINIQUE LA PRAIRIE RES SA , WESTPHAL OTTO , WAELLI THIERRY , GORCZYNSKI REGINALD , MUELLER SILKE , MACH JEAN-PIERRE , HARTMANN ALFRED , BESSLER WOLFGANG , HOFMANN PETRA , ZAEHRINGER ULRICH , ALEXANDER CHRISTIAN , VOR DEM ESCHE ULRICH , ULMER ARTUR J , VERDINI ANTONIO
发明人： WESTPHAL OTTO , WAELLI THIERRY , GORCZYNSKI REGINALD , MUELLER SILKE , MACH JEAN-PIERRE , HARTMANN ALFRED , BESSLER WOLFGANG , HOFMANN PETRA , ZAEHRINGER ULRICH , ALEXANDER CHRISTIAN , VOR DEM ESCHE ULRICH , ULMER ARTUR J , VERDINI ANTONIO
IPC分类号： A61K35/407 , A61K35/74 , A61K38/00 , A61K38/17 , A61K38/42 , A61K39/02 , A61P35/00 , A61P37/00
CPC分类号： A61K35/407 , A23L33/10 , A61K35/74 , A61K38/42 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition representing a novel immunomodulating principle comprising bacterial endotoxin, fetal hemoglobin or more particularly a heme-free derivative or the gamma-chain thereof, and optionally, components which are present in the fetal liver in addition to HbF. The composition is delivered to humans in a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention it was surprisingly found that endotoxin and fetal hemoglobin partial structures display a pronounced synergistic biomedical activity. The biomedical effect of fetal hemoglobin and its partial structures is surprisingly not based on a classical hemoglobin function as an oxygen transporter but related to a modulation of endotoxin-mediated bioactivity. This biomedical activity is surprisingly also observed after oral application of the composition. The composition of the invention finds a variety of applications which have in common the stimulation of the immune system and the reversion in polarization of cytokines and chemokines from a Th2-directed response to a Th1-type response. The proposed applications would therefore include the treatment of allergic conditions, malignancies, chronic infections, autoimmune phenomena and age-related imbalances.
摘要翻译：本发明涉及代表包含细菌内毒素，胎儿血红蛋白或更特别是不含血红素的衍生物或其γ链，以及除了HbF之外存在于胎肝中的成分的新的免疫调节原理的药物组合物。组合物以药学上可接受的载体和/或稀释剂递送给人。根据本发明，惊奇地发现内毒素和胎儿血红蛋白部分结构显示出明显的协同生物医学活性。胎儿血红蛋白及其部分结构的生物医学效应令人惊讶地不是基于作为氧转运蛋白的经典血红蛋白功能，而是与内毒素介导的生物活性的调节有关。在口服施用组合物后，也观察到该生物医学活性。本发明的组合物发现各种各样的应用，其具有共同的刺激免疫系统和从Th2导向的Th1型反应的细胞因子和趋化因子的极化反转。因此，所提出的申请将包括治疗过敏性疾病，恶性肿瘤，慢性感染，自身免疫现象和年龄相关的不平衡。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式